Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jinchai Antiviral Capsule is a traditional Chinese medicine (TCM) formulation developed by the China Academy of Chinese Medical Sciences Institute of Chinese Materia Medica. It is indicated for the treatment of the common cold, specifically targeting the 'wind-heat' pattern in TCM, which is characterized by symptoms such as fever, headache, cough, and sore throat. The drug is composed of multiple herbal extracts intended to provide broad-spectrum antiviral, anti-inflammatory, and antipyretic effects. It has been evaluated in Phase 3 randomized, double-blind, placebo-controlled clinical trials in China to establish its safety and efficacy in relieving symptoms associated with upper respiratory tract infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jinchai Antiviral Capsule.